Korean Journal of Head & Neck Oncology (대한두경부종양학회지)

The Korean Society for Head and Neck Oncology (대한두경부종양학회)
권호 표지

Immunohistochemical Expression of Galectin-3, Cytokeratin 19 and HBME-1 in Papillary Microcarcinoma of the Thyroid Gland

갑상선 미세 유두암종에서 Galectin-3, Cytokeratin 19와 HBME-1의 발현

  • Kim, Jin-Hwan (Department of Pathology, Keimyung University School of Medicine) ;
  • Lee, Sang-Sook (Department of Pathology, Keimyung University School of Medicine)
  • 김진환 (계명대학교 의과대학 병리학교실) ;
  • 이상숙 (계명대학교 의과대학 병리학교실)
  • Published : 2007.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

With the wide use of ultrasonography and fine needle aspiration of the thyroid gland, the incidence of papillary microcarcinoma of the thyroid gland is rapidly increasing nowadays. To improve the diagnostic accuracy of histopathologic findings of papillary thyroid carcinoma, various molecular markers have been used recently. We analysed the expression of galectin-3, cytokeratin 19 and HBME-1, using immunohistochemical technique in 37 cases of papillary microcarcinoma of the thyroid gland to evaluate the diagnostic value of these molecular markers. Immunohistochemically, galectin-3 expression was found in 37 cases of papillary microcarcinoma. Its localization was mostly cytoplasmic. Cytokeratin 19 expression was found in 36 cases. It was mostly localized to the cytoplasm and membrane. HBME-1 expression was found in all cases. Its localization was plasma membrane. The expression of these three molecular markers was negative in the adjacent normal thyroid tissue and accompanying benign lesions, although there are scattered foci of incomplete positive staining in cases of Hashimoto's thyroiditis. Our findings suggest that the immunohistochemical staining using antibodies for galectin-3, cytokeratin 19 and HBME-1 is an useful adjunctive method for the histopathological diagnosis of a papillary microcarcinoma of the thyroid gland.

갑상선 미세유두암종은 영상 기술의 발달로 더욱 그 빈도가 높아질 것이 예상되므로 진단의 정확도를 높이는 것이 무엇보다 중요하다. 갑상선 미세 유두암종으로 진단 받은 37예를 대상으로 galectin-3, cytokeratin 19와 HBME-1 분자 표지자들을 면역조직화학적 염색을 시행한 결과 cytokeratin 19에서 1예를 제외하고 모든 예에서 갑상선 종양 세포에서 발현하였다. Galectin-3는 갑상선 종양 세포의 세포질에 강하게 염색되었으며 cytokeratin 19는 세포질과 세포막을 따라 강하게 염색되었다. HBME-1은 종양 세포의 세포막에 강하게 염색되었으나 3가지 분자 표지자 모두 정상 갑상선 조직에서는 염색되지 않았다. 이상의 결과에서 볼 때 galectin-3, cytokeratin 19와 HBME-1은 병리조직학적 소견과 함께 갑상선 미세 유두암종을 진단함에 있어 보조적 도움이 되는 표지자로 생각된다.

Keywords

References

  1. Gharib H: Current evaluation of thyroid nodules. Trends Endocrinol Metab. 1994;5:365-369 https://doi.org/10.1016/1043-2760(94)90103-1
  2. Mazzaferri EL: Management of a solitary thyroid nodule. N Engl J Med. 1993;328:553-558 https://doi.org/10.1056/NEJM199302253280807
  3. Chow SM, Law SCK, Chan JKC, et al: Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31-40 https://doi.org/10.1002/cncr.11442
  4. Piersanti M, Ezzat S, Asa SL: Controversies in papillary microcarcinoma of the thyroid. Endocrine Pathol. 2003;l4:183-192 https://doi.org/10.1007/s12022-003-0011-5
  5. Li Volsi VA: Surgical pathology of the thyroid. Philadelphia. Saunders, 1990
  6. Rosai J, Carcagiu ML, DeLellis RA: Tumors of thyroid gland. In: Atlas of tumor pathology, Fascicle 5, 3rd Series. Washington, DC. Armed Forces Institute of Pathology, 1992
  7. Rosai J: Ackerman's surgical pathology. St Louis. Mosby Co., 2004
  8. Aratake Y, Umeki K, Kiyoyama K, et al: Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol. 2002;26:366-372 https://doi.org/10.1002/dc.10111
  9. Casey MB, Lohse CM, Lloyd RV: Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol. 2003;14:55-60 https://doi.org/10.1385/EP:14:1:55
  10. Garcia S, Vassko V, Henry JF, De Micco C: Comparison of thyroid peroxidase expression with cellular proliferation in thyroid follicular tumors. Thyroid. 1998;8:745-759 https://doi.org/10.1089/thy.1998.8.745
  11. Zeiger MA, Smallridge RC, Clark DP, et al: Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasm. Surgery. 1999;126:1195-1198 https://doi.org/10.1067/msy.2099.101374
  12. Park MI, Kang DY: Usefulness of galectin-3, cytokertin 19, p53, and Ki-67 for the differential diagnosis of thyroid tumors. Korean J Pathol. 2006;40:86-92
  13. Cvejic D, Savin S, Petrovic I, et al: Galecin-3 expression in papillary microcarcinoma of the thyroid. Histopathology. 2005;47:209-214 https://doi.org/10.1111/j.1365-2559.2005.02199.x
  14. Barondes SH, Cooper DVW, Gitt MA, et al: Galectins: structure and function of a large family of animal lectins. J Biol Chem. 1994;69:20807-20810
  15. Hapke M, Dehner LP: The optically clear nucleus. A reliable sign of papillary carcinoma of the thyroid? Am J Surg Pathol. 1979;3:31-38 https://doi.org/10.1097/00000478-197902000-00004
  16. Xu XC, El Naggar AK, Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol. 1995;147:815-822
  17. Giannini R, Faviana P, Cavinato T, et al: Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid. 2003;13:765-770 https://doi.org/10.1089/105072503768499662
  18. Beesley MF, McLaren KM: Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology. 2002;41:236-243 https://doi.org/10.1046/j.1365-2559.2002.01442.x
  19. Orlandi F, Saggiorato E. Pivano G, et al: Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998;58:3013-3020
  20. Nikiforova MN, Lynch RA, Biddinger PW, et al: RAS point mutations and PAX8-PPAR rearrangement in thyroid tumors. Evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88:2318-2326 https://doi.org/10.1210/jc.2002-021907
  21. Prasad ML, Huang Y, Pellegata NS, et al: Hashimoto's thyroiditis with papillary thyroid carcinoma-like nuclear alterations express molecular markers. Histopathology. 2004;45:39-46 https://doi.org/10.1111/j.1365-2559.2004.01876.x
  22. van Hoeven KH, Kovatich AJ, Miettinen M: Immunocytochemical evaluation of HBME-1, CA 19-9, and CD-5 (Leu-M1) in fine-needle aspirates of thyroid nodules. Diagn Cytopathol. 1998;18:93-97
  23. Sack MJ, Astengo-Osuna C, Lin BT, et al: HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol. 1997;10:668-674